S&P 500   4,583.22 (-0.05%)
DOW   36,114.64 (+-0.01%)
QQQ   391.03 (+0.15%)
AAPL   194.71 (+0.23%)
MSFT   372.58 (+0.44%)
META   329.29 (+0.83%)
GOOGL   135.01 (-1.40%)
AMZN   146.72 (-0.11%)
TSLA   244.06 (+0.59%)
NVDA   475.11 (+1.96%)
NIO   7.45 (-0.53%)
BABA   72.09 (-0.33%)
AMD   128.48 (+0.09%)
T   16.95 (-0.82%)
F   11.01 (+1.76%)
MU   74.45 (+1.09%)
CGC   0.77 (+6.73%)
GE   120.15 (+0.56%)
DIS   93.24 (+0.96%)
AMC   7.00 (+2.64%)
PFE   28.81 (+0.63%)
PYPL   59.14 (+1.13%)
XOM   99.21 (+0.80%)
S&P 500   4,583.22 (-0.05%)
DOW   36,114.64 (+-0.01%)
QQQ   391.03 (+0.15%)
AAPL   194.71 (+0.23%)
MSFT   372.58 (+0.44%)
META   329.29 (+0.83%)
GOOGL   135.01 (-1.40%)
AMZN   146.72 (-0.11%)
TSLA   244.06 (+0.59%)
NVDA   475.11 (+1.96%)
NIO   7.45 (-0.53%)
BABA   72.09 (-0.33%)
AMD   128.48 (+0.09%)
T   16.95 (-0.82%)
F   11.01 (+1.76%)
MU   74.45 (+1.09%)
CGC   0.77 (+6.73%)
GE   120.15 (+0.56%)
DIS   93.24 (+0.96%)
AMC   7.00 (+2.64%)
PFE   28.81 (+0.63%)
PYPL   59.14 (+1.13%)
XOM   99.21 (+0.80%)
S&P 500   4,583.22 (-0.05%)
DOW   36,114.64 (+-0.01%)
QQQ   391.03 (+0.15%)
AAPL   194.71 (+0.23%)
MSFT   372.58 (+0.44%)
META   329.29 (+0.83%)
GOOGL   135.01 (-1.40%)
AMZN   146.72 (-0.11%)
TSLA   244.06 (+0.59%)
NVDA   475.11 (+1.96%)
NIO   7.45 (-0.53%)
BABA   72.09 (-0.33%)
AMD   128.48 (+0.09%)
T   16.95 (-0.82%)
F   11.01 (+1.76%)
MU   74.45 (+1.09%)
CGC   0.77 (+6.73%)
GE   120.15 (+0.56%)
DIS   93.24 (+0.96%)
AMC   7.00 (+2.64%)
PFE   28.81 (+0.63%)
PYPL   59.14 (+1.13%)
XOM   99.21 (+0.80%)
S&P 500   4,583.22 (-0.05%)
DOW   36,114.64 (+-0.01%)
QQQ   391.03 (+0.15%)
AAPL   194.71 (+0.23%)
MSFT   372.58 (+0.44%)
META   329.29 (+0.83%)
GOOGL   135.01 (-1.40%)
AMZN   146.72 (-0.11%)
TSLA   244.06 (+0.59%)
NVDA   475.11 (+1.96%)
NIO   7.45 (-0.53%)
BABA   72.09 (-0.33%)
AMD   128.48 (+0.09%)
T   16.95 (-0.82%)
F   11.01 (+1.76%)
MU   74.45 (+1.09%)
CGC   0.77 (+6.73%)
GE   120.15 (+0.56%)
DIS   93.24 (+0.96%)
AMC   7.00 (+2.64%)
PFE   28.81 (+0.63%)
PYPL   59.14 (+1.13%)
XOM   99.21 (+0.80%)

BioMarin Pharmaceutical Stock Price, News & Analysis (NASDAQ:BMRN)

$92.67
-2.27 (-2.39%)
(As of 11:39 AM ET)
Compare
Today's Range
$92.62
$94.33
50-Day Range
$76.22
$94.94
52-Week Range
$76.02
$117.77
Volume
422,118 shs
Average Volume
1.41 million shs
Market Capitalization
$17.46 billion
P/E Ratio
120.35
Dividend Yield
N/A
Price Target
$112.65

BioMarin Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.61 Rating Score
Upside/​Downside
18.7% Upside
$112.65 Price Target
Short Interest
Healthy
1.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.93
Upright™ Environmental Score
News Sentiment
1.12mentions of BioMarin Pharmaceutical in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
84.75%
From $1.18 to $2.18 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

42nd out of 960 stocks

Pharmaceutical Preparations Industry

9th out of 381 stocks


BMRN stock logo

About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BMRN Stock Price History

BMRN Stock News Headlines

Energy Storage Trend Ignites Frenzy Over Vanadium Supply
As the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.
Energy Storage Trend Ignites Frenzy Over Vanadium Supply
As the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.
Oppenheimer Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)
BioMarin: Keeping Bullish View After Q3 Earnings
See More Headlines
Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BMRN
CUSIP
09061G10
Employees
3,082
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$112.65
High Stock Price Target
$185.00
Low Stock Price Target
$78.00
Potential Upside/Downside
+18.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.61
Research Coverage
23 Analysts

Profitability

Net Income
$141.56 million
Pretax Margin
6.56%

Debt

Sales & Book Value

Annual Sales
$2.10 billion
Cash Flow
$1.51 per share
Book Value
$24.82 per share

Miscellaneous

Free Float
184,902,000
Market Cap
$17.88 billion
Optionable
Optionable
Beta
0.40

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report














BMRN Stock Analysis - Frequently Asked Questions

Should I buy or sell BioMarin Pharmaceutical stock right now?

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 9 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BMRN shares.
View BMRN analyst ratings
or view top-rated stocks.

What is BioMarin Pharmaceutical's stock price target for 2024?

23 brokers have issued 1-year price targets for BioMarin Pharmaceutical's stock. Their BMRN share price targets range from $78.00 to $185.00. On average, they expect the company's stock price to reach $112.65 in the next year. This suggests a possible upside of 18.7% from the stock's current price.
View analysts price targets for BMRN
or view top-rated stocks among Wall Street analysts.

How have BMRN shares performed in 2023?

BioMarin Pharmaceutical's stock was trading at $103.49 at the start of the year. Since then, BMRN stock has decreased by 8.3% and is now trading at $94.94.
View the best growth stocks for 2023 here
.

Are investors shorting BioMarin Pharmaceutical?

BioMarin Pharmaceutical saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 3,080,000 shares, a drop of 6.4% from the October 31st total of 3,290,000 shares. Based on an average trading volume of 1,520,000 shares, the days-to-cover ratio is currently 2.0 days.
View BioMarin Pharmaceutical's Short Interest
.

When is BioMarin Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our BMRN earnings forecast
.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by $0.02. The biotechnology company had revenue of $581.33 million for the quarter, compared to analyst estimates of $603.51 million. BioMarin Pharmaceutical had a net margin of 6.36% and a trailing twelve-month return on equity of 4.45%.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its fourth quarter earnings guidance on Wednesday, November, 1st. The company provided earnings per share (EPS) guidance of $0.08-0.28 for the period, compared to the consensus earnings per share estimate of $0.27. The company issued revenue guidance of $617-697 million, compared to the consensus revenue estimate of $652.66 million.

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (9.77%), Barclays PLC (2.96%), Ameriprise Financial Inc. (2.74%), Fort Washington Investment Advisors Inc. OH (0.70%), Charles Schwab Investment Management Inc. (0.69%) and Northern Trust Corp (0.65%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier and V Bryan Lawlis.
View institutional ownership trends
.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BMRN) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -